Markets rallied strongly this week on clarity about the election and an expected rate cut, but next week's inflation readings will determine if momentum lasts
If you're patient, these businesses have a lot of promising projects in the works.
A cancer drug has vast potential for the company, says a pundit newly following it.
Summit Therapeutics Inc. aims to advance Ivonescimab, a potential breakthrough for NSCLC. The FDA's Fast Track designation boosts its U.S. clinical pathway.
The price could be right for these stocks.
These are the kinds of stocks that can allow investors to sleep easy at night.
Should you add these fast-growing stocks to your portfolio?
The potential upside of this stock is undeniably meaty.
This drugmaker's lead candidate could become a top-selling cancer therapy.
Millennium Management just initiated a position in a small biotech company developing a new cancer drug.